CD274 and non-small cell lung carcinoma: These percentages agree substantially with previously reported data on the NSCLC mutational landscape [20,21] Anti-PD-L1 immunoreactivity was detected in 42.0% (score 0), 37.8% (score 1), and 20.2% (score 2) of cases (Table 1).